Alterations due to dilution and anticoagulant effects in hematologic analysis of rodent blood samples on the Sysmex XT‐2000iV          下载免费PDF全文

Kaitlin A. Moorhead  Marielle L. Discipulo  Jing Hu  Roberta C. Moorhead  Jennifer L. Johns 《Veterinary clinical pathology / American Society for Veterinary Clinical Pathology》2016,45(2):215-224

  相似文献   

Reducing blood volume requirements for clinical pathology testing in toxicologic studies—points to consider          下载免费PDF全文

Florence Poitout‐Belissent  Adam Aulbach  Niraj Tripathi  Lila Ramaiah 《Veterinary clinical pathology / American Society for Veterinary Clinical Pathology》2016,45(4):534-551

In preclinical safety assessment, blood volume requirements for various endpoints pose a major challenge. The goal of this working group was to review current practices for clinical pathology (CP) testing in preclinical toxicologic studies, and to discuss advantages and disadvantages of methods for reducing blood volume requirements. An industry‐wide survey was conducted to gather information on CP instrumentation and blood collection practices for hematology, clinical biochemistry, and coagulation evaluation in laboratory animals involved in preclinical studies. Based on the survey results and collective experience of the authors, the working group proposes the following “points to consider” for CP testing: (1) For most commercial analyzers, 0.5 mL and 0.8 mL of whole blood are sufficient for hematology and biochemistry evaluation, respectively. (2) Small analyzers with low volume requirements and low throughput have limited utility in preclinical studies. (3) Sample pooling or dilution is inappropriate for many CP methods. (4) Appropriate collection sites should be determined based on blood volume requirements and technical expertise. (5) Microsampling does not provide sufficient volume given current analyzer and quality assurance requirements. (6) Study design considerations include: the use of older/larger animals (rodents), collection of CP samples before toxicokinetic samples, use of separate subsets of mice for hematology and clinical biochemistry testing, use of a priority list for clinical biochemistry, and when possible, eliminating coagulation testing.  相似文献